

REMARKS

Applicants request the entry of this Supplemental Amendment being filed in response to the Interview conducted with Examiner Wessendorf on December 18, 2006.

Claims 4-6, 8-10, 13-22 and 32-33 have been cancelled without prejudice or disclaimer. Applicants reserve the right to file one or more continuation applications including the subject matter of these claims.

Claims 1 and 23 have been amended. The amendments are supported throughout the specification, including at page 10, line 30 to page 11, line 12.

INTERVIEW

Applicants thank Examiner Wessendorf for the interview on December 18, 2006. We discussed the 112 rejection and claim amendments that could overcome the rejection. We discussed allowable subject matter.

112, FIRST PARAGRAPH ISSUES

In the Final Office Action, the Examiner rejected claims 1-3, 7-12 and 20-23 for lack of written description. The Examiner contends that Applicants do not have written description to support A3 with a length up to 12 amino acids. Applicants traverse.

While not acquiescing to the rejection and solely to expedite prosecution, Applicants claims now refer to A3 as a tetrapeptide. Applicants respectfully request withdrawal of this rejection.

Applicants further submit with respect to claim 23, a fusion protein having 1-50 amino acids at N and C terminal end, independently is supported throughout the specification, including at page 10, lines 30 to page 11, line 12. Phage display methods are described, for example, at page 15, line 19 to page 18, line 8. Specific examples of peptides having single amino acid added at the N and C terminal ends are provided, for example, in Table 2 and at page 29, lines 1-12. Peptides b, d and f show fusion peptides as claimed with a single amino in the acid X1 and X2 positions, at the N and C terminal ends of the peptide. A specific example of peptides fused to gene 8 of M13 is shown at page 35, lines 3-34.

Applicants further note that the example also indicates the cyclic peptide can be linked to a GD epitope tag and linker that provides for high level phage display. Translating the inserted sequence shows the sequence Ser-Ala-Ser-Ala-Tyr-Ala-Xaa-Cys-Thr-Trp-Xaa-Xaa-Xaa-Xaa-Leu-Thr-Cys-Xaa-Met-Ala-Asp-Pro-Asn-Arg. See the specification at page 35. A library was developed from this construct and provided binders to the target receptor. Thus, Applicants have described and exemplified several species of the fusion protein of claim 23 and one of skill in the art would understand that Applicants were in possession of the claimed subject matter.

INTERVIEW REQUEST

Applicants request an interview with the Examiner to resolve any remaining issues.


SUMMARY

Applicants submit that all pending claims are in condition for allowance, and notification to that effect is earnestly solicited. The Examiner is invited to contact Applicants' representative if prosecution may be assisted thereby.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: December 19, 2006


Katherine M. Kowalchyk
Reg. No. 36,848
KMK:sab

